Catalog No.
Product Name
Application
Product Information
Citations
-
HIV replication inhibitor
Feglymycin is a HIV replication inhibitor. Feglymycin is also an antibiotic peptide that has antibacterial activity (MIC: 32-64 μg/mL for Staphylococcus aureus). -
HIV-1 protease/PTP1B inhibitor
Isosinensetin is a bioactive flavonoid compound with diverse pharmacological properties. It acts as a dual inhibitor of HIV-1 protease and protein tyrosine phosphatase 1B (PTP1B), with an IC₅₀ of 2.61 µM and a Kᵢ of 0.92 µM for PTP1B, indicating its potential in antiviral and metabolic disease research. Additionally, isosinensetin inhibits P-glycoprotein (P-gp) activity in MDR1-MDCKII cells, suggesting its utility in overcoming multidrug resistance. Isosinensetin exhibits multiple therapeutic effects, including anti-tumor, anti-viral, anti-inflammatory, and antioxidant activities. These properties support its application in the research of various conditions such as cancer, chronic inflammation, osteoporosis, diabetes, and infectious diseases. -
HIV Reverse Transcriptase Inhibitor
β-Rubromycin is a selective inhibitor of HIV-1 reverse transcriptase, exhibiting a Ki of 0.27 μM. Additionally, it demonstrates potent telomerase inhibition with an IC50 of 3 μM. β-Rubromycin effectively inhibits the proliferation of K-562 and HeLa cell lines, showing IC50 values of 19.5 µM and 22.7 µM, respectively, making it a valuable tool for research in HIV and telomerase-related studies. -
HIV Protease Inhibitor
Cytochalasin A is a cell-permeable fungal toxin that is an oxidized derivative of cytochalasin B. Cytochalasin A is an inhibitor of HIV-1 protease (IC50=3 μM) and inhibits actin polymerization and interferes with microtubule assembly by reacting with sulfhydryl groups. Antibiotic and fungicidal activitives. -
HIV-1 Entry Inhibitor
Trilobatin is a natural sweetener extracted from Lithocarpus polystachyus Rehd, functioning primarily as an HIV-1 entry inhibitor by targeting the HIV-1 Gp41 envelope protein. It demonstrates neuroprotective effects and acts as a selective SGLT1/2 inhibitor, promoting the proliferation of human hepatoblastoma cells. Trilobatin is valuable for research involving HIV-1 entry mechanisms and potential therapeutic applications in hepatoblastoma and neuroprotection studies. -
Anti-HIV Agent
Oleanonic acid, a triterpene, primarily targets anti-HIV activity. It exhibits notable anti-inflammatory properties and can ameliorate conditions associated with oxidative stress, autophagy dysfunction, ferroptosis, mitochondrial damage, and endoplasmic reticulum stress, particularly induced by Amyloid-β in vitro. Additionally, oleanonic acid has been demonstrated to reduce myocardial hypertrophy in rat models in vivo, highlighting its potential for therapeutic applications in cardiovascular and neurodegenerative research. -
Antifungal/antimitotic/anti-HIV-1 Agent
Wikstrol A is a potent antifungal, antimitotic, and anti-HIV-1 agent that primarily targets fungal and viral proliferation. This compound induces significant morphological deformation of the mycelia of P. oryzae, with a minimum effective concentration (MMDC) of 70.1 µM, and demonstrates inhibition of microtubule polymerization with an IC50 value of 131 µM. Furthermore, Wikstrol A exhibits anti-HIV-1 activity, showcasing an IC50 value of 67.8 µM, making it relevant in therapeutic research against both fungal infections and HIV-1. -
Antifungal Agent/HIV-1 Inhibitor
Amphotericin B methyl ester hydrochloride is a derivative of the polyene antibiotic amphotericin B, functioning primarily as an antifungal agent. This compound exhibits potent antifungal activity by binding to cholesterol in fungal cell membranes, leading to cell death. Additionally, it disrupts HIV-1 particle production and significantly inhibits HIV-1 replication, making it valuable for research in antifungal therapies and HIV treatment studies. -
Antifungal Agent/HIV-1 Inhibitor
Amphotericin B methyl ester is a methyl ester derivative of the polyene antibiotic Amphotericin B, targeting cell membranes through cholesterol binding. Exhibiting potent antifungal activity, it effectively disrupts the structural integrity of fungal cells. Additionally, Amphotericin B methyl ester has demonstrated the ability to inhibit HIV-1 particle production and replication, making it valuable for research in both antifungal therapies and HIV-1 studies. -
HIV Protease Inhibitor
Indinavir is a selective inhibitor of HIV-1 protease, displaying a Ki value of 0.54 nM, making it a potent antiviral agent. In addition to its primary role in HIV treatment, Indinavir has demonstrated anticancer properties by inhibiting matrix metalloproteinases (MMPs) and promoting anti-angiogenic effects, alongside inducing apoptosis in cancer cells. Furthermore, Indinavir has shown inhibitory activity against the SARS-CoV 3CL protease, expanding its potential applications in viral research. -
HIV Protease Inhibitor
Indinavir sulfate ethanolate is a selective inhibitor of HIV-1 protease, demonstrating a potent Ki of 0.54 nM for the target enzyme. Beyond its antiviral activity, this compound has shown potential in anticancer research through the inhibition of MMPs-2 activation, anti-angiogenic effects, and promotion of apoptosis. Additionally, Indinavir sulfate ethanolate acts as an inhibitor of the SARS-CoV 3CLpro enzyme, highlighting its diverse biological activity and relevance in multiple research applications. -
Anti-HIV Agent
Moronic Acid is a triterpenoid compound that serves as an orally available anti-HIV agent, exhibiting significant anti-inflammatory properties. It demonstrates the ability to inhibit viral replication, with an EC50 value of less than 1 μg/mL. Moronic Acid can be isolated from Brazilian propolis and is utilized in research focused on HIV treatment and related viral studies. -
HIV-Ⅰ Inhibitor
HIV-IN-6 is an inhibitor of HIV-1 viral replication, specifically targeting Src family kinases (SFKs) that associate with the viral Nef protein, including Hck. This compound has demonstrated significant antiviral activity by disrupting the functional interactions necessary for viral pathogenesis. Its application in research includes the study of HIV infection mechanisms and the exploration of novel therapeutic strategies against HIV-1. -
HIV Integrase Inhibitor
Equisetin is an N-methylserine-derived acyl tetramic acid that functions as a potent HIV integrase inhibitor. It specifically interferes with the activity of HIV-1 integrase and demonstrates notable inhibition of 11β-HSD1 and Dnp-stimulated ATPase, with an IC50 of approximately 8 nmol per mg of protein. Additionally, Equisetin exhibits significant antibacterial properties, anti-inflammatory effects, and potential benefits in managing lipid-associated disorders while also showcasing cytotoxic activity. This compound is valuable for research applications focused on HIV treatment and the exploration of antimicrobial and anti-inflammatory mechanisms. -
HIV NNRTI
(Rac)-Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates significant antiviral activity with a Ki of 2.93 nM for the inhibition of the wild-type HIV-1 reverse transcriptase and an IC95 of 1.5 nM against HIV-1 replication in cultured cells. This compound is suitable for research applications focusing on HIV-1 therapy and the development of antiretroviral drugs. -
HIV-1 RT Inhibitor
Apricitabine is a selective inhibitor of HIV-1 reverse transcriptase (RT) with a Ki value of 0.08 μM. It also exerts inhibitory effects on DNA polymerases α, β, and γ, with corresponding Ki values of 300 μM, 12 μM, and 112.25 μM. Demonstrating significant antiretroviral efficacy and favorable tolerability, Apricitabine shows a reduced potential for resistance development in patients with antiretroviral-naive HIV infection. This compound is applicable for research in the mechanisms of HIV-1 replication and antiviral drug development. -
DNA Synthesis/HSV/HIV-1 Inhibitor
16,16-Dimethyl prostaglandin A1 is a prostaglandin analog that primarily inhibits DNA synthesis. It demonstrates significant antiviral activity by reducing viral replication in both herpes simplex virus (HSV) and HIV-1 infection models. This compound serves as a valuable tool for research focused on cancer biology and viral pathogenesis. -
HIV-1 Reverse Transcriptase Inhibitor
R82913 (9-Cl-TIBO) is a selective inhibitor of HIV-1 reverse transcriptase, demonstrating significant antiviral activity against both RNA and DNA templates crucial for viral replication. This compound effectively inhibits the replication of various HIV-1 strains in CEM cells, with a median IC50 value of 0.15 μM. It serves as a valuable reagent for research applications focused on HIV therapy development and reverse transcriptase inhibition studies. -
HIV Inhibitor
Fozivudine tidoxil is an orally active HIV inhibitor designed as a thioether lipid-zidovudine (ZDV) conjugate. This compound exhibits potent anti-HIV activity by incorporating into the newly synthesized DNA strand during viral replication, leading to irreversible binding to viral reverse transcriptase and disruption of the reverse transcription process. In addition to its antiviral properties, Fozivudine tidoxil is also a versatile click chemistry reagent, capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with suitable alkyne or DBCO/BCN-containing molecules, making it valuable for chemical biology applications. -
HIV-1 Inhibitor
HIV-1 Inhibitor-43 is a selective inhibitor targeting the HIV-1 virus. It demonstrates potent efficacy with an EC50 of 21.3 nM for Y188L mutants, 6.2 nM for K103N-Y181C, and under 0.7 nM for both K103N and Y181C strains. This compound effectively reduces HIV-1 RNA levels and protein p24 expression, making it a valuable tool for research in HIV pathogenesis and therapeutic development. -
DENV/HIV-1 Inhibitor
DENV-IN-5 is a potent inhibitor targeting both dengue virus (DENV) and HIV-1 replication. It demonstrates effective antiviral activity with half-maximal effective concentration (EC50) values of 1.47, 9.23, 7.08, and 8.91 μM against DENV serotypes I to IV, respectively. Additionally, DENV-IN-5 inhibits the HIV-1 IIIB strain with an EC50 of 0.1512 μM. This compound is valuable for research focused on viral infections and the development of antiviral therapies. -
HIV/HBV Inhibitor
L-2'-Fd4C is an L-nucleoside analogue that acts as an inhibitor of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV). This compound exhibits potent antiviral activity, making it valuable for research focused on the treatment and understanding of these viral infections. Its unique mechanism of action may provide insights into the development of novel therapeutic strategies against HIV and HBV. -
HIV-1 Inhibitor
SJP-L-5 is an HIV-1 capsid dissociation inhibitor that targets the HIV-1 viral capsid, preventing its normal function. It demonstrates significant inhibitory activity against various HIV-1 strains, with an EC50 ranging from 0.16 to 0.97 μg/mL. By effectively blocking the entry of HIV-1 viral DNA into the nucleus, SJP-L-5 offers valuable potential for applications in HIV-1 infection research and development of antiviral therapies. -
Anti-HIV Agent
3′-Azido-2′,3′-dideoxy-CTP (AZddCTP) is a cytidine analog that serves as an anti-HIV agent by acting as a chain terminator. Incorporated into the nascent DNA strand by HIV reverse transcriptase, AZddCTP halts DNA synthesis due to its lack of a 3'-hydroxyl group, effectively inhibiting viral replication. With IC50 values of 15.6 μM against wild-type HIV and 160.8 μM for AZTR HIV, 3′-Azido-2′,3′-dideoxy-CTP demonstrates significant antiviral activity, making it a valuable tool in HIV research. -
HIV Inhibitor
ZL0580 is an HIV inhibitor that functions by selectively binding to the BD1 domain of BRD4, leading to epigenetic suppression of the virus. This compound effectively inhibits Tat transactivation and transcription elongation while promoting a repressive chromatin structure at the HIV promoter. ZL0580 is valuable for research applications focused on HIV therapies and the mechanisms of viral transcription regulation. -
HIV-1 LRA
UMB-136 is a bromodomain inhibitor targeting HIV-1 latency. It serves as a promising latency-reversing agent (LRA) for the eradication of HIV-1, effectively reactivating the virus in various cell models. UMB-136 enhances HIV-1 transcription and promotes viral production by facilitating the release of P-TEFb, thereby contributing to research in HIV treatment strategies. -
HIV Inhibitor
Ilimaquinone is a marine sponge-derived compound that functions as an HIV inhibitor. It exhibits anti-HIV activity along with anti-inflammatory, antimicrobial, and anticancer properties, primarily through the GADD153-mediated pathway. Additionally, Ilimaquinone has been shown to induce vesiculation of the Golgi apparatus, making it a valuable tool for research on viral infections and cellular mechanisms. -
HIV-1 Inhibitor
Formycin A is a purine nucleoside antibiotic that acts as a potent inhibitor of human immunodeficiency virus type 1 (HIV-1), exhibiting an EC50 of 10 μM. This compound demonstrates notable antiviral and antitumor activities, making it a valuable tool for research in virology and cancer biology. Its efficacy against HIV-1 makes it a relevant candidate for studies aimed at developing antiviral therapies. -
HIV-1 Protease Inhibitor
(Rac)-PD 135390 is a potent HIV-1 protease inhibitor, exhibiting an IC50 of 2 nM. This dipeptide is instrumental in antiviral research, providing insights into HIV-1 protease activity and potential therapeutic interventions. Its efficacy in inhibiting viral replication makes it a valuable tool for studying HIV pathogenesis and drug resistance. -
HIV Protease Inhibitor
Palinavir is a potent inhibitor of HIV-1 and HIV-2 proteases, exhibiting an IC50 range of 0.5-30 nM. It demonstrates significant antiviral activity, making it valuable for research focused on HIV treatment strategies and drug development. Palinavir's mechanism of action targets the viral protease enzyme, disrupting the replication cycle of the virus and providing insights into HIV pathogenesis and therapeutic interventions. -
HIV-1 Protease Inhibitor
Lasinavir (CGP 61755) is a selective inhibitor of HIV-1 protease, exhibiting an IC50 value of 1 nM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for studying HIV-1 infection and pathogenesis. Lasinavir is applicable in research focused on antiretroviral therapies and the mechanism of protease inhibition in viral replication. -
HIV Protease Inhibitor
L-689502 is a potent HIV protease inhibitor with an IC50 of 1 nM. This compound effectively disrupts the proteolytic activity of HIV-1 protease, thereby inhibiting viral replication. L-689502 is valuable for research into antiretroviral therapies and mechanisms of HIV resistance. -
HIV-1 Capsid Inhibitor
Lenacapavir is an HIV-1 capsid inhibitor that targets the interface between capsid hexamers and CA monomers, disrupting capsid assembly and viral maturation. This compound inhibits the nuclear translocation of HIV-1 DNA and interferes with CA-mediated protein-protein interactions, resulting in reduced formation of 2-LTR circles and pre-integration proviruses. Additionally, Lenacapavir induces aberrant capsids and decreases the production of mature HIV-1. It demonstrates efficacy against various HIV-1 subtypes and clinical isolates, making it a valuable reagent for research on HIV-1 infection. -
HIV-1 RT Inhibitor
Tenofovir diphosphate disodium is a potent inhibitor of HIV-1 reverse transcriptase, with a Ki value of 1.55 μM for DNA and 0.022 μM for RNA. This compound exhibits key biological activity as an antiretroviral agent, making it a valuable tool for the study of HIV and AIDS. It is suitable for research applications focused on understanding viral replication and developing therapeutic strategies against HIV infection. -
HIV-1 TAT Peptide
TAT (YGRKKRRQRRR) is a cell-penetrating peptide derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1). It enhances the solubility and yield of heterologous proteins, making it a valuable tool in research applications related to protein expression and purification. TAT's ability to facilitate cellular uptake has made it a useful reagent in studies exploring intracellular delivery mechanisms and molecular therapeutics. -
HIV-1 Inhibitor
PYR01 is a non-nucleoside reverse transcriptase inhibitor that targets HIV-1 by activating the death of infected cells. It exhibits significant antiviral activity, demonstrating IC50 values of 27.5 nM and 39.7 nM for cytotoxic and antiviral effects, respectively. By promoting HIV-1 Gag-Pol dimerization and intracellular activation of HIV-1 protease, PYR01 induces selective cytotoxicity in HIV-1-infected cells. This compound is valuable for research focused on HIV biology and therapeutic strategies. -
HIV-1 Inhibitor
PF-3450074 is a specific inhibitor of the HIV-1 capsid protein (CA), exhibiting broad-spectrum antiviral activity against various HIV isolates with submicromolar potency (EC50=8-640 nM). This compound functions at an early stage of the HIV-1 life cycle, impeding viral replication by competing with the binding of nuclear host factors CPSF6 and NUP153. Additionally, PF-3450074 disrupts key processes such as uncoating, assembly, and reverse transcription, making it a valuable tool for HIV research. -
CD4-Targeted HIV Inhibitor
Cyclotriazadisulfonamide (CADA) is a selective inhibitor of HIV entry that targets CD4. It functions by inhibiting the co-translational translocation of human CD4 into the endoplasmic reticulum lumen in a signal peptide-dependent manner. In addition, CADA acts as a Sec61 translocon inhibitor, making it a valuable tool for studying HIV pathogenesis and potential therapeutic strategies against HIV infection. -
HIV-1 Inhibitor
Glycolithocholic acid 3-sulfate is a cholic acid derivative that serves as an effective HIV-1 inhibitor. It demonstrates the ability to inhibit the replication of HIV-1 in vitro, making it a valuable tool for studying HIV infection. Additionally, Glycolithocholic acid 3-sulfate may have relevance in research related to gallbladder disease. -
V-ATPase/HIV-1 Inhibitor
Diphyllin is a potent inhibitor of vacuolar H+-ATPase (V-ATPase) with an IC50 of 17 nM, and also acts as an HIV-1 inhibitor with an IC50 of 0.38 μM. This compound effectively disrupts the acidification of osteoclast lysosomes, leading to significant inhibition of osteoclast-mediated bone resorption while leaving osteoblastic bone formation unaffected. Diphyllin is valuable for investigating bone metabolism-related diseases and exploring therapeutic avenues for conditions characterized by excessive bone resorption. -
HIV Inhibitor
Censavudine is a nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. With EC50 values ranging from 30 nM to 81 nM for HIV-2 and 450 nM to 890 nM for HIV-1, this compound is effective in disrupting viral replication. Additionally, Censavudine possesses a reactive alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a versatile tool for click chemistry applications in drug development and molecular biology research. -
HIV gag mRNA Antagonist
Trecovirsen is an antiviral agent that targets HIV gag mRNA by hybridizing with its complementary sequence at the initiation site. This interaction leads to the induction of a reversible, dose-dependent prolongation of activated partial thromboplastin time due to its polyanionic properties. Trecovirsen is applicable for research on HIV infection, providing insights into the mechanisms of viral replication and potential therapeutic strategies. -
HIV/NRTTI Inhibitor
MK-8527 is an orally active inhibitor of HIV that functions as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). This compound exhibits antiviral activity by impeding reverse transcriptase, an essential enzyme for viral replication. MK-8527 is primarily utilized in research focused on the development of HIV therapeutic strategies and studying mechanisms of resistance in retroviral infections. -
HIV Inhibitor
2',3'-Dideoxyadenosine is an inhibitor of HIV replication that functions by incorporating into viral DNA, thereby terminating chain elongation. This compound exhibits significant antiretroviral activity and is utilized in research to understand mechanisms of HIV infection and the development of therapeutic strategies against the virus. Its efficacy makes it a valuable tool in antiviral studies and drug development pipelines focused on HIV. -
HIV-1 Polypeptide
HIV-1 TAT (48-60) is a cell-penetrating peptide derived from residues 48-60 of the HIV-1 Tat protein, functioning as a facilitator for cellular uptake. This peptide enables the effective delivery of exogenous macromolecules into cells without causing disruption to cellular integrity. Its unique mechanism enhances research applications in drug delivery, gene therapy, and the study of intracellular processes associated with HIV-1. -
HIV Inhibitor
Zingibroside R1 is a dammarane-type triterpenoid saponin that targets HIV through its inhibitory effects. Isolated from the rhizomes, taproots, and lateral roots of Panax japonicus C. A. Meyer, it demonstrates anti-HIV-1 activity, in addition to notable anti-tumor and anti-angiogenic properties. Zingibroside R1 also inhibits 2-deoxy-D-glucose (2-DG) uptake in EAT cells with an IC50 of 91.3 μM, highlighting its potential for further research in cancer and viral therapies. -
HIV Inhibitor
(R)-Edelfosine, also known as (R)-ET-18-OCH3, is an ether lipid analog that primarily targets HIV through its antiviral properties. This compound exhibits significant anti-HIV activity and demonstrates potential antineoplastic effects. It is commonly utilized in research applications related to antiviral therapies and cancer treatment investigations. -
HIV-1 reverse transcriptase Inhibitor
Ulonivirine is an orally active non-nucleoside inhibitor of HIV-1 reverse transcriptase, targeting the hydrophobic binding pocket adjacent to the enzyme's polymerase active site. It effectively disrupts viral replication, making it a valuable tool for research focused on HIV-1 infection and the mechanisms of antiretroviral resistance. Ulonivirine is suitable for studies aimed at understanding HIV-1 pathogenesis and developing therapeutic interventions. -
HIV-1 Integrase Inhibitor
Bictegravir sodium is a highly potent inhibitor of HIV-1 integrase, demonstrating an IC50 of 7.5 nM. This compound exhibits robust and selective anti-HIV activity while maintaining low cytotoxicity. Bictegravir sodium is primarily utilized in research focused on HIV treatment strategies and the development of antiretroviral therapies. -
HIV-1 Integrase Inhibitor
1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide is a potent inhibitor of HIV-1 integrase, targeting both the 3'-processing and strand transfer stages of the integration process. This compound serves as a valuable tool in HIV-1 research, facilitating the study of viral replication and integration mechanisms. Its effectiveness in inhibiting key steps in the integration pathway makes it an important reagent for investigations related to HIV-1 therapeutic development.
